Juvenescence is encouraged by Bank of America Merrill Lynch’s recent report, ‘Immortal combat – Future Human Primer’, where their analysts have highlighted the impending growth of longevity-focused companies.
They estimate that the market for ‘techmanity’, technology to increase human lifespan, is “worth USD $110Bn today, growing at a 28% CAGR to USD $610Bn by 2025”.
It is promising to see financial experts recognize that we can add an unprecedented number of healthy years onto the human lifespan. The report importantly highlights that the next generation of rejuvenative, aging-modifying therapies will likely have the impact of “improving human longevity to live freer of disease rather than forever”, as we enter “an era of healthceleration, where advances in technology could bring about a quantum leap in the quality and length of human lives”. Encouragingly, the report also discusses how recent scientific breakthroughs are challenging engrained beliefs and refer to aging as a disease amenable to intervention.
Greg Bailey, CEO of Juvenescence, commented:
“It is a very positive sign that Bank of America Merrill Lynch has joined Citibank, Credit Suisse and Julius Baer in recognizing that modifying or slowing the aging process will be tractable in the short term and worthy of attention from the wider investor community. Juvenescence’s founders have found that a portfolio approach to age modification will mitigate the typical risks associated with biotechnology companies and dramatically improve its chances of successfully bringing products to market. Currently, there are only a handful of companies taking a portfolio approach to addressing aging.
Looking to the future, we are excited by the prospect of pioneering the massive market described by Bank of America Merrill Lynch and others and are very confident in our approach to develop therapeutic agents that modify aging and increase healthy lifespan.”